Clinical Oncology News: SABCS 2016: Everolimus Added to Fulvestrant Upped PFS in Postmenopausal HR+ Breast Ca Pts

December 1, 2016

Adding everolimus to fulvestrant in postmenopausal women with hormone receptor (HR)-positive/HER2-negative, aromatase inhibitor (AI)-resistant metastatic breast cancer improved progression-free survival (PFS) to 10.4 months, compared with 5.1 months for fulvestrant alone, in the randomized, double-blind, Phase II PrECOG 0102 trial. Read the full  story at Clinical Oncology News


Philly Purge: Merck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection

December 1, 2016

Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the presentation of results from three Phase 2 clinical trials evaluating MK-3682B (MK-3682/grazoprevir/ruzasvir1), the company’s investigational all-oral, triple-combination regimen for the treatment of chronic hepatitis C (HCV) infection (informally referred to as MK3). Read the full story at Philly Purge